Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: BXRX =MC $52 M--FDA Decision in Q1 for attractive Drug

No earlier versions found for this Subject.

Return to BXRX =MC $52 M--FDA Decision in Q1 for attractive Drug

Market-Cap $49 Million-- Cash $19 Million or untill end 2020 -- Shares Out 9.1 Million -- Potential FDA approval for their lead drug Anjeso (non-opioid pain reliever ) in Q1 2020 which has HUGE market potential .MASSIVE underpriced Low float stock with significant upside potential here ..My target is $20+ by end of next year .GL

Baudax Bio (BXRX)

Market Cap 49 M
Cash $19 M
Price $5.45

Shares Out 9.1 M

New Presentation (december 2019)
d1io3yog0oux5.cloudfront.net

Janney starts Baudax Bio at buy; fair value estimate $12
biotuesdays.com

Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.

She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”